Chengtao Li
李成涛
Chengtao Li is the founder and CEO of Galixir (星药科技), an AI-driven drug discovery company. He holds a bachelor's degree from Tsinghua University's Yao Class and a PhD in computer science from MIT, and has published multiple papers at top AI conferences, positioning him as a leading researcher at the intersection of AI and chemistry . Under his leadership, Galixir has raised tens of millions of dollars in funding from investors including 5Y Capital and Gaorong Capital, with its platform demonstrating the ability to identify novel molecular candidates with better activity than reference drugs and greater patent freedom . Li has framed the company's mission as making new medicines accessible to patients through AI-powered innovation . Elsewhere's corpus does not contain more recent material on his activities beyond 2021.
AI-generated — may contain errors, please verify.
Coverage
Medtech Entrepreneurship Is a "Game for the Brave": How to Sharpen Innovation, Product, and Organizational Capabilities | Ronghui
Discussing trends in medical technology innovation and upgrading R&D team organizational management.
高榕创投·5Y News | Galixir Completes New Strategic Funding Round, Continues Advancing Drug R&D Pipeline
5Y Capital continues to watch for opportunities where information technology can be applied in healthcare and medicine.
五源资本·5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
五源资本·Rongbao · January | E-commerce and Retail Players Build Out Origin-Region Supply Chains; Multiple Chip, AI, and Enterprise Service Firms Close New Funding Rounds
Discover and accompany creators of a beautiful life.
高榕创投·Galixir's Chengtao Li: Finding the "Key" to Curing Disease with AI in the Universe of Compounds | Rong Talk --- In the vast "universe" of chemical compounds, finding the molecule that can precisely target a disease is like searching for a needle in a haystack — except the haystack contains more stars than there are in the Milky Way. This is where Galixir comes in. Founded in 2019, Galixir is an AI-driven drug discovery company that uses artificial intelligence to navigate the astronomical complexity of molecular space. At its helm is Chengtao Li, a Tsinghua University PhD who spent years at MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL) before returning to China to build what he calls "a new kind of pharmaceutical R&D engine." "The traditional drug discovery process is incredibly inefficient," Li tells us in a wide-ranging conversation at the company's Beijing headquarters. "You're talking about 10 to 15 years and $2-3 billion to bring a single drug to market. And the failure rate is brutal. We think AI can fundamentally change that equation." Galixir's approach centers on what Li describes as "generative chemistry" — using deep learning models to design novel molecules from scratch, rather than merely screening existing compound libraries
How artificial intelligence technology is accelerating drug discovery and development.
高榕创投·Galixir Announces Tens of Millions of Dollars in Funding, Using "AI+" to Break Through Bottlenecks in Drug Discovery
Gaorong Ventures led Galixir's angel round and continued to increase its stake in subsequent funding rounds.
高榕创投·5Y News | Galixir Announces Completion of Tens of Millions of USD in Funding, with Continued Backing from 5Y Capital
Breaking the Bottleneck in New Drug R&D with "AI+"
五源资本·The Collision of AI and Pharmaceuticals: Galaxy Pharma Tech Raises Nearly $10 Million in Funding | Light Moments
Galixir announced the completion of a nearly $10 million Pre-A funding round. The round was co-led by Source Code Capital and DCM, with 5Y Capital participating as a follow-on investor. Gaorong Capital, the lead investor in the company's angel round, continued to increase its stake.
五源资本·
